Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126845211 | 12684521 | 1 | I | 20160818 | 20160825 | 20160825 | PER | US-GLAXOSMITHKLINE-US2016121204 | GLAXOSMITHKLINE | 0.00 | F | Y | 0.00000 | 20160825 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126845211 | 12684521 | 1 | PS | WELLBUTRIN SR | BUPROPION HYDROCHLORIDE | 1 | 100 MG, QD | U | 20358 | 100 | MG | PROLONGED-RELEASE TABLET | QD | ||||||
| 126845211 | 12684521 | 2 | C | ASPIRIN. | ASPIRIN | 1 | U | 0 | |||||||||||
| 126845211 | 12684521 | 3 | C | BYSTOLIC | NEBIVOLOL HYDROCHLORIDE | 1 | U | 0 | |||||||||||
| 126845211 | 12684521 | 4 | C | WELLBUTRIN | BUPROPION HYDROCHLORIDE | 1 | 75 MG, UNK | U | 0 | 75 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126845211 | 12684521 | 1 | Depression |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126845211 | 12684521 | Fatigue | |
| 126845211 | 12684521 | Somnolence |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126845211 | 12684521 | 1 | 20160814 | 0 | ||
| 126845211 | 12684521 | 4 | 2016 | 0 |